Eric Easom
Chief Executive Officer at AN2 Therapeutics Inc.
Sits on 1 board. Last updated September 27, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: AN2 Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
AN2 Therapeutics Inc. May 22, 202568.1%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 20, 2026 | AN2 Therapeutics Inc. | Grant or award | +112,250 | — | — |
| Jun 2, 2025 | AN2 Therapeutics Inc. | Open-market purchase | +10,000 | $1.07 | $10,700 |
| Feb 26, 2025 | AN2 Therapeutics Inc. | Grant or award | +145,250 | — | — |
| Nov 18, 2024 | AN2 Therapeutics Inc. | Open-market purchase | +50,000 | $1.00 | $50,000 |
| Mar 15, 2024 | AN2 Therapeutics Inc. | Grant or award | +99,000 | — | — |
| Jan 2, 2024 | AN2 Therapeutics Inc. | Open-market sale | −2,777 | $20.09 | $55,790 |
| May 15, 2023 | AN2 Therapeutics Inc. | Open-market purchase | +10,000 | $5.38 | $53,800 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.